Hillenbrand Industries

Size: px
Start display at page:

Download "Hillenbrand Industries"

Transcription

1 25 Hillenbrand Industries 25 Third Quarter Investor Information Financial Highlights Dollars in millions, except per share data Nine Months Ended Nine Months Ended Reporting Period 6/3/5 6/3/ Revenues $1,441.5 $1,355.2 $1,829.3 $ 1,693.9 Net income $ $ 47.7 $ 19.6 $ 138. Diluted EPS - GAAP $ 2.18 $.76 $ 1.75 $ 2.22 The results above were negatively (positively) impacted by the following items which are more fully discussed in our filings on Forms 1-K and 1-Q: Nine Months Ended Nine Months Ended Reporting Period 6/3/5 6/3/ Net income from above $135.6 $ 47.7 $ 19.6 $ 138. Realized capital gains/losses and bond impairments unrelated to portfolio management $ $ (2.4) $ (2.4) $ 32.6 CMS claims resolution $ $ $ $ (2.) Accelerated depreciation for plant closure $.2 $ $ $ Severance and benefit costs, asset impairments, and other realignment activities $ 2.4 $ (.9) $ 3.4 $ 6.2 Impairment of rental fleet assets $ 1.1 $ $ $ Loss on extinguishment of debt $ $ 4. $ 4. $ 1.4 Loss on disposal of discontinued operations $ (.1) $ $ 15.1 $ 51. Net income adjusted for above items $139.2 $ $ $ About Hillenbrand Industries, Inc. Hillenbrand Industries, Inc. (NYSE:HB) is the holding company for two businesses in the health care and funeral services industries. The Company and its individual operating companies, all based in Batesville, Indiana, employ about 1,4 associates worldwide. Its oldest business, Batesville Casket Company, was founded in The Hill-Rom Company, a maker and provider of patient care equipment and services, was founded in Financial Goals Annual revenue growth + 1% Annual earnings per share growth + 15% Hillenbrand Industries intends to increase revenue annually by 1 percent while improving earnings by 15 percent across the business cycle. The intention is to perform in the top 1 percent of companies in the S&P 5 based on total return to shareholders. Hillenbrand Industries, Inc. 7 State Route 46 E Batesville, IN Healthier Lives. Easier Transitions.

2 Hillenbrand by the Numbers Hillenbrand Industries Dollars in millions, except per share data Nine Months Ended Nine Months Ended Twelve Months Ended 6/3/5 6/3/4 9/3/4 9/3/3 Revenues $ 1,441.5 $ 1,355.2 $1,829.3 $1,693.9 Gross profit Other operating expenses Special charges (credits) 5.5 (1.4) Operating profit Other income (expense), net 2.7 (13.7) (12.7) (51.) Income from continuing operations before tax Income tax expense Income from continuing operations $ $ $ $ 18.6 Diluted earnings per share from continuing operations $ 2.17 $ 2.27 $ 3. $ 2.9 Gross profit percentage 46.3% 5.2% 49.6% 52.2% Effective tax rate 37.% 4.6% 38.9% 35.6% Dividends per share $.84 $.81 $ 1.8 $ 1. Average shares outstanding - diluted 62,253 62,63 62,725 62,185 Depreciation, amortization & write-down of intangibles $ 86.8 $ 76.1 $ 18.1 $ 75.1 Capital expenditures Operating cash flow Debt/capitalization 24.4% 28.1% 25.3% 12.2% ROE (1) 17.9% 4.8% 1.1% 12.3% Shareholders N/A N/A 17, 16,9 Employees 1,4 9,9 1,4 9,9 (1) Rolling 12 months Business Drivers A leader in each business we serve. Superior customer intimacy. High-quality, high-margin, innovative product lines. Favorable demographics aging America driving demand. Commitment to continuous improvement. Health care spending as a percentage of gross domestic product increasing. Commitment to research and development in order to introduce new products. A keen focus on increasing operating efficiencies, controlling expenses and optimizing the product portfolio. Comprehensive yet efficient distribution system. Targeted acquisitions and divestitures to increase revenue and earnings growth. Why invest in Hillenbrand? 1. Financial strength to support profitable growth. 2. Operating companies have leadership positions in their businesses. 3. Operating management that finds ways to grow faster than their industries through new product innovation and superior customer service. 4. Operating companies in relatively non-cyclical markets. 5. Focused, realistic, well-financed strategies for growth in place. 6. Energetic new management team with corporate development experience. 7. Management compensation aligned with shareholders interests. Financial Strengths Exceptionally strong balance sheet. Improving liquidity and float. Stock repurchase program, launched in the mid 198s. Purchased 22.7 million shares, authorized to purchase another 1.6 million shares. Long history of dividend increases. HB 2 25

3 History At A Glance 196 Batesville Coffin Company purchased and name changed to Batesville Casket Company under the leadership of John A. Hillenbrand John W. Hillenbrand named President of Batesville Casket Company William A. Hillenbrand founded Hill-Rom; President from 1929 until G.C. Hillenbrand, inventor holding more than 4 patents belonging to both Hill-Rom and Batesville Casket Company, introduced the first mass produced metal gasketed casket Daniel A. Hillenbrand named President of Batesville Casket Company. Hillenbrand Industries formed and John W. Hillenbrand named President, CEO and Chairman of the Board Hillenbrand Industries listed on the NYSE for $36.5 a share ($1.14 today on a post split basis) W August (Gus) Hillenbrand named President of Hill-Rom Hillenbrand Industries acquired SSI Medical Services now Hill-Rom s Therapy Rental business Hillenbrand Industries established Forethought Financial Services with Frederick W. Rockwood named President W August (Gus) Hillenbrand named President and CEO of Hillenbrand Industries. 2 Rockwood named President and CEO of Hillenbrand Industries. First non-hillenbrand family President and CEO. 21 Daniel A. Hillenbrand named Chairman Emeritus. Ray J. Hillenbrand named Chairman of the Board of Hillenbrand Industries. R. Ernest Waaser named Hill-Rom President and CEO. Kenneth A. Camp named Batesville Casket President and CEO. Stephen R. Lang named Forethought President and CEO. Hillenbrand Board members George M. Hillenbrand, II, and Lawrence R. Burtschy retire. Hill-Rom introduced the TotalCare SpO 2 RT system. 22 Board members Peter Coffaro, Edward Davis and Leonard Granoff retire. Hillenbrand names health care executives Charles Golden of Eli Lilly & Company, Rolf Classon of Bayer HealthCare, AG and Peter Soderberg of Welch Allyn to the Board. 23 Rolf A. Classon named Vice-Chairman of the Board. Anne Griswold Peirce, R.N., Ph.D. and Joanne C. Smith, M.D. named to the Board. Daniel A. Hillenbrand and John C. Hancock retire from the Board. 24 Hillenbrand sells Hill-Rom s infant care and piped-medical gas businesses and acquires Mediq, Inc., Advanced Respiratory, Inc. and Navicare Systems, Inc. Hillenbrand also sells Forethought Financial Services. New Board Members are Mark D. Ketchum and Eduardo Menascé. Hill-Rom introduces the VersaCare Bed. 25 Rockwood retires, Rolf A. Classon named Interim President and CEO of Hillenbrand Industries. Net Revenues Income From Continuing Operations Net Cash Provided By Operating Activities Dividends Per Share Diluted Earnings Per Share From Continuing Operations (dollars) (dollars) 2, , , Revenues By Business Segment Quarterly Stock Performance (high to low in dollars) Stock Price Range (high and low in dollars) Batesville Casket 35% Hill-Rom 65% All charts presented on a twelve month basis ended September 3 of 22, 23 and 24 corresponding to the company s new fiscal year-end of September 3. Oct-Dec Jan-Mar Apr-Jun Jul-Sep HB 3 25

4 Operating Companies Hill-Rom Health Care Revenues 1,2 Hill-Rom is a leading provider of patient care products and services for the acute care, long-term care and home care environments. Hill-Rom s offerings include: facility assessments, patient care beds, stretchers, therapy surfaces, workflow products, moveable medical equipment, nurse communication systems, headwall systems, patient room furniture and professional services.hill-rom employs about 6, workers worldwide. Hill-Rom reported fiscal 24 revenues of $1.2 billion. Company Origin Hill-Rom was formed in 1929 by William A. Hillenbrand. The company produced wooden furniture that would make hospitals more comfortable and make patients feel more at home Rental Health Care Gross Profits 6 2 (1) 3 4 Capital Hill-Rom Financial Information Nine Nine Months Ended Months Ended Twelve Months Ended Dollars in millions 6/3/5 6/3/4 9/3/4 9/3/3 Sales: Revenues $ $ $ $ Cost of goods sold $ $ $ $ Gross margin 44.8% 47.7% 48.1% 5.6% Rentals: Revenues $ $ $ $ Cost of goods sold $ $ $ $ 16.6 Gross margin 39.% 46.6% 44.8% 49.4% (1) 12 months ended 9/3/2 for comparison purposes. Transition fiscal year was 1 months ended 9/3/2. Health Care Trends Creating Opportunities for Hill-Rom Rental 2 (1) 3 4 Capital U.S. and European inpatient admissions are increasing. Demand for health care is increasing due to: Population growth; Aging of America (Fastest growing age groups, especially people who are 84 and older, are those that are most in need of medical care); Critical nursing shortage throughout the U.S. and the average age of nurses is increasing. Health care providers under pressure to control costs, improve the quality and efficiency of patient care. Capital spending by hospitals for renovations or new construction is increasing. Improved diagnostics. Heightened consumer expectations. Growing demand for hospital capacity. Nurse Communication Systems ActiveCare DVT TranStar Procedural Stretcher HB 4 25

5 Businesses Capital Sales About 62 percent of Hill-Rom s fiscal 24 revenues from continuing operations were generated by capital sales to hospitals, ambulatory and long-term care centers. The company participates in more than a third of the global hospital capital equipment business. The company s premier product, the TotalCare Bed System, provides onebutton conversion from a prone to seated position. This feature reduces caregiver related injuries associated with repositioning, lifting or transferring a patient and makes it easier for some patients to become ambulatory sooner. The TotalCare Bed System and Hill-Rom s other bed systems, including it s VersaCare and CareAssist lines, demonstrates Hill-Rom s value proposition: Improved opportunities for positive outcomes for the patient; safety and efficiency for the caregiver; and increased productivity and cost savings for the provider. Rental About 38 percent of Hill-Rom s fiscal 24 revenues from continuing operations were generated through rental of specialized therapy patient support surfaces, beds for wound and pulmonary therapy, and for managing complications associated with patient immobility. The global rental business is about $1 billion a year. The rental program at Hill-Rom allows our customers to utilize the most up-to-date specialty beds and surfaces without the associated capital investment. This proven program is cost effective for facilities and efficient for their staff. Rental program features include: 17 nursing professionals for clinical consultation; Highly trained service representatives; and, Over 2 service locations worldwide. Hill-Rom s CLINITRON RITE HITE Air Fluidized Therapy Unit bed is one example of its rental product offerings. This bed provides pressure relief for advanced wounds, greater comfort for patients, and ease for caregivers. It features a unique combination of Air Fluidized Therapy and Low Air-loss Therapy on an articulating frame. Sales Force More than 7 worldwide salespeople focused on creating and maintaining superior customer relationships. Hill-Rom sales representatives and a network of independent distributor representatives are located in 1+ countries. Hill-Rom also has U.S. and European customer showrooms and visitation programs. Distribution Approximately 785-unit transportation fleet Approximately 114 trailers Hill-Rom Company Facilities Headquarters 169 State Route 46 East Batesville, IN Acton, MA Operating room accessories Batesville, IN Beds, stretchers, furniture, headwalls, columns Cary, NC Nurse communication systems Charleston, SC Therapeutic surfaces and non-invasive devices Montpellier, France Therapeutic surfaces Pluvigner, France Beds, furniture St. Paul, MN Respiratory care products National Service Centers Network of nearly 25 global capital and therapy rental service centers with 2 in North America CLINITRON RITE HITE Air Fluidized Therapy Unit bed TotalCare Bed Systems VersaCare Bed System The Vest Airway Clearance System HB 5 25

6 Operating Companies Batesville Casket Funeral Services Revenues 8 Batesville Casket Company is a leading producer of burial caskets. The company also provides cremation urns and caskets, and offers full marketing support services to licensed funeral homes. Batesville Casket employs about 3,6 associates and reported fiscal 24 revenues of $64 million. Company Origin Founded in 1884 as Batesville Coffin Company, the company was rescued from bankruptcy by the Hillenbrand family in 196. It is now one of several casket manufacturers with company-owned nationwide delivery capabilities Batesville Casket Financial Information Nine Nine Months Ended Months Ended Twelve Months Ended Dollars in millions 6/3/5 6/3/4 9/3/4 9/3/3 Funeral Services sales $ 51.4 $ $ 64.3 $ Funeral Services cost of goods sold $ $ 22.5 $ 29.1 $ Funeral Services gross margins 53.2% 55.3% 54.7% 55.6% (1) 12 months ended 9/3/2 for comparison purposes. Transition fiscal year was 1 months ended 9/3/2. 2 (1) 3 4 Batesville s Market Funeral Services Gross Profits (1) 3 4 Batesville Casket s customers are licensed funeral directors operating licensed funeral homes. Batesville Casket holds a strong presence in the North American burial casket industry and is a leading and growing player in cremation products. There are about 22, North American licensed funeral homes, of which about 75 percent are independently owned enterprises. The small, independently owned and operated licensed funeral home is Batesville Casket s core customer base. However, the company also serves a number of the national funeral service providers. In 24, the company launched its Dimensions by Batesville product line in response to funeral directors, who have continued to ask us to provide them with additional models and styles of caskets that provide greater interior width as well as our innovative personalization features. This new product line consists of a full selection of larger-sized burial and cremation caskets. Batesville Casket's Strengths Strong customer relationships through a direct sales force and unique customer visitation program. Unmatched logistics provide the ability to reach two-thirds of funeral home customers with next day service. Industry leading manufacturing with the broadest product line. Low-cost manufacturer through continuous improvement. Ever expanding list of value added features. Capital Cherry MemorySafe drawer MarsellusTM by Batesville HB 6 25

7 Funeral Services Trends North American annual death rate is 2.6 million and flat to increasing about one-half of one percent. An estimated one-third of funeral services are cremations and the remainder are burials. Consumers, especially baby boomers, are interested in personalizing funeral services and products. Batesville Casket Ensuring Continued Profitability U.S. Licensed Funeral Homes (Approximately 22,) Independently Owned 75% National/ Consolidated Funeral Homes 25% Reduces unprofitable stock keeping units, improving product mix. Innovates new personalized products and services. Controls costs and supply chain management. Improves efficiency. Installing enterprise resource planning system. Expands overnight customization of caskets. This can include sculpted LifeSymbols corner designs, personalization of the interior of the casket or other aspects of the unit, and MemorySafe drawers for storing personal items inside the casket itself. Participates in the cremation market with its Options line of cremation caskets, urns and related keepsakes. Provides funeral home retail display and consultation business with System Solutions by Batesville. Launches the Marquetry Collection, a new line of high-quality engineered wood caskets that incorporates the styles and designs of fine home furniture. Reintroduces the Marsellus line of caskets to independent funeral directors. Burial Casket Market Batesville Casket s leadership position, customer focus and innovative products have allowed it to create shareholder value in the flat-to-declining burial casket business. 3,, Total Deaths Cremations Burials 2,5, 2,, 1,5, 1,, 5, Sales Force Approximately 15 North American salespeople Distribution Six regional distribution centers Approximately 8 local customer service centers throughout North America Approximately 585-unit transportation fleet Approximately 5 trailers Batesville Casket Facilities Headquarters One Batesville Boulevard Batesville, Indiana Batesville, IN Metal casket manufacturing Cremation product manufacturing Batesville, MS Wood casket manufacturing Chihuahua, Mexico Wood casket manufacturing Manchester, TN Metal casket manufacturing Mexico City, Mexico Metal casket manufacturing Nashua, NH Wood casket manufacturing Vicksburg, MS Wood processing Freedom s Glory cast bronze urn Mom LifeSymbols casket corner design Golden Pearl 18 gauge steel casket with Rose LifeSymbols corner design DimensionsTM by Batesville HB 7 25

8 HILLENBRAND INDUSTRIES OFFICERS HILLENBRAND INDUSTRIES BOARD OF DIRECTORS Rolf A. Classon, 59 Interim President and Chief Executive Officer* Bruce Bonnevier, 46 Vice President, Human Resources Kenneth A. Camp, 59 President and Chief Executive Officer, Batesville Casket Company, Inc. and Vice President, Hillenbrand Industries, Inc.* Patrick D. de Maynadier, 44 Vice President, General Counsel and Secretary* Kimberly K. Dennis, 38 Vice President, Shared Services* Gregory N. Miller, 42 Senior Vice President and Chief Financial Officer * Larry V. Baker, 5 Vice President, Corporate Tax Mark R. Lanning, 5 Vice President and Treasurer Gary Larson, 43 Vice President, Audit Wendy Wilson, 52 Vice President, Investor Relations and Corporate Communications * Member, Corporate Executive Management Team Ray J. Hillenbrand, 7 Chairman of the Board Hillenbrand Industries Private Investor Rolf A. Classon, 59 Interim President and Chief Executive Officer Hillenbrand Industries Chairman Bayer HealthCare Charles E. Golden, 58 Executive Vice President and Chief Financial Officer Eli Lilly and Company John A. Hillenbrand II, 73 Personal Investments W August Hillenbrand, 64 Personal Investments Mark D. Ketchum, 55 President, Global Baby and Family Care (retired) The Proctor and Gamble Company Eduardo Menascé, 59 President, ESG Verizon Communications Anne Griswold Peirce, R.N., Ph.D., 53 Associate Dean for Academic Affairs and Associate Professor of Clinical Nursing Columbia University School of Nursing Joanne C. Smith, M.D., 43 Interim Vice Chairwoman of the Board of Directors Senior Vice President, Corporate Strategy and Business Development Rehabilitation Institute of Chicago Peter H. Soderberg, 58 President and Chief Executive Officer Welch Allyn, Inc. CONTACT INFORMATION Investors: Wendy Wilson Vice President, Investor Relations and Corporate Communications Hillenbrand Industries, Inc. 7 State Route 46 East Batesville, Indiana Phone: Fax: wendy.wilson@hillenbrand.com For more information about Hillenbrand or its subsidiaries, Batesville Casket Company and Hill-Rom, please visit the company s Internet site DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS Certain statements in this fact sheet contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding our future plans, objectives, beliefs, expectations, representations and projections. We have tried, whenever possible, to identify these forward-looking statements by using words such as intend, anticipate, believe, plan, encourage, expect, may, goal, become, pursue, estimate, strategy, will, projection, forecast, continue, accelerate, promise, increase, or the negative of those terms or other variations of them or by comparable terminology. The absence of such terms, however, does not mean that the statement is not forward-looking. It is important to note that forward-looking statements are not guarantees of future performance, and our actual results could differ materially from those set forth in any forward looking statements. Factors that could cause actual results to differ from forward-looking statements include but are not limited to the factors discussed under the heading Risk Factors in the Company s Annual Report on Form 1-K. We assume no obligation to update or revise any forward-looking statements. HB 8 25 Printed 9/25

HILLENBRAND INDUSTRIES INC

HILLENBRAND INDUSTRIES INC HILLENBRAND INDUSTRIES INC FORM 8-K (Unscheduled Material Events) Filed 2/17/2004 For Period Ending 2/13/2004 Address 700 STATE ROUTE 46 E BATESVILLE, Indiana 47006-8835 Telephone 812-934-7000 CIK 0000047518

More information

January 30, 2018 Dow Wilson President and Chief Executive Officer

January 30, 2018 Dow Wilson President and Chief Executive Officer Acquisition of SIRTeX January 30, 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking

More information

FORM8-K HILLENBRAND,INC.

FORM8-K HILLENBRAND,INC. UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION Washington,D.C.20549 FORM8-K CURRENTREPORT PursuanttoSection13or15(d)oftheSecuritiesExchangeActof1934 Date of Report (Date of earliest event reported): December18,2015

More information

Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs

Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs Second quarter sales up 3.1 percent to record $17.0 billion

More information

ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015

ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 1 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation

More information

Q Investor Kit JANUARY-JUNE 2014

Q Investor Kit JANUARY-JUNE 2014 Q2 2014 Investor Kit JANUARY-JUNE 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco

More information

Q Investor Kit JANUARY-MARCH 2014

Q Investor Kit JANUARY-MARCH 2014 Q1 2014 Investor Kit JANUARY-MARCH 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco

More information

FY2007 Consolidated Financial Overview

FY2007 Consolidated Financial Overview FY2007 Consolidated Financial Overview CHUGAI PHARMACEUTICAL CO., LTD. Executive Vice President and CFO Ryuzo Kodama January 30/31, 2008 Forward-Looking Statements This presentation may include forward-looking

More information

1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes

1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes 1Q 2015 Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes Forward-Looking Statements and Copyright This Presentation includes and is based, inter alia, on forward-looking information and statements

More information

ResMed Inc. 36 th Annual J.P. Morgan Healthcare Conference

ResMed Inc. 36 th Annual J.P. Morgan Healthcare Conference ResMed Inc. 36 th Annual J.P. Morgan Healthcare Conference Mick Farrell CEO January 8, 2018 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking

More information

Hyundai Motor Company 1 st Quarter 2011 Business Results. April 28, 2011

Hyundai Motor Company 1 st Quarter 2011 Business Results. April 28, 2011 Hyundai Motor Company 1 st Quarter 2011 Business Results April 28, 2011 Cautionary Statement with Respect to Forward-Looking Statements In the presentation that follows and in related comments by Hyundai

More information

Q Investor Kit January December 2014

Q Investor Kit January December 2014 Q4 2014 Investor Kit January December 2014 Highlights for Q4 Sales up for all product areas and operating profit from product areas up by 8% Scandinavian hoarding for snus prior to tax increase in January

More information

Walgreens (WAG) Analyst: Juan Fabres Fall 2014

Walgreens (WAG) Analyst: Juan Fabres Fall 2014 Recommendation: Buy Target Price August 31, 2016: $77.57 1. Reasons for the Recommendation With the acquisition of Alliance Boots in Europe, Walgreens will be the first US pharmacy to operate retail stores

More information

BALCHEM CORPORATION. Q Investor Relations Presentation

BALCHEM CORPORATION. Q Investor Relations Presentation BALCHEM CORPORATION Q4 2017 Investor Relations Presentation Balchem Corporation Balchem develops, manufactures, and markets specialty ingredients that improve and enhance the health and well being of life

More information

Q Investor Kit JANUARY-JUNE 2013

Q Investor Kit JANUARY-JUNE 2013 Q2 2013 Investor Kit JANUARY-JUNE 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)

More information

Q Investor Kit JANUARY-MARCH 2013

Q Investor Kit JANUARY-MARCH 2013 Q1 2013 Investor Kit JANUARY-MARCH 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)

More information

Annual Shareholders Meeting

Annual Shareholders Meeting Annual Shareholders Meeting February 8, 2018 Dow R. Wilson, President and Chief Executive Officer Forward-Looking Statements Except for historical information, this presentation contains forward-looking

More information

For personal use only

For personal use only Cochlear Limited Results for the half year ended 31 December 2011 (H1 F12) Chris Roberts, CEO Neville Mitchell, CFO Cochlear Overview Cochlear Limited (ASX:COH): global leader in implantable devices for

More information

Investor Presentation. Q April 26, 2018

Investor Presentation. Q April 26, 2018 Investor Presentation Q3 2018 April 26, 2018 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking statements as contemplated by the Private Securities

More information

Shareholder Presentation Annual Meeting 2018

Shareholder Presentation Annual Meeting 2018 Shareholder Presentation Annual Meeting 2018 FY 18 HIGHLIGHTS Strong sales growth of 2 nd Gen TruScreen to China commenced during 4 th quarter. (50% of the year s sales were generated in the fourth quarter)

More information

Summary of Results for the First Half of FY2015/3

Summary of Results for the First Half of FY2015/3 Summary of Results for the First Half of FY2015/3 November 10, 2014 Tokyu Corporation (9005) http://www.tokyu.co.jp/ Contents Ⅰ.Executive Summary 2 Ⅱ.Conditions in Each Business 5 Ⅲ.Details of Financial

More information

Uroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011

Uroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011 Uroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011 Forward Looking Statement This presentation includes forward-looking statements, including financial projections, relating

More information

For personal use only

For personal use only HY18 Result Presentation 13 February 2018 Dig Howitt Brent Cubis CEO & President CFO HY18 Result highlights Strong momentum across developed markets continues Developed market unit growth up 12% Strengthening

More information

Financial Presentation

Financial Presentation Financial Presentation Certain of the statements that will be made during this meeting, as well as statements contained in our 2006 Annual Report to Shareholders and Annual Report on Form 10-K filed with

More information

Investor Presentation. Q October 26, 2017

Investor Presentation. Q October 26, 2017 Investor Presentation Q1 2018 October 26, 2017 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking statements as contemplated by the Private

More information

Telekom Austria Group Results for the 1st Quarter May 27, 2003

Telekom Austria Group Results for the 1st Quarter May 27, 2003 Telekom Austria Group Results for the 1st Quarter 2003 May 27, 2003 1 Cautionary Statement This presentation contains certain forward-looking statements. Actual results may differ materially from those

More information

Letter to Shareholders SEMI-ANNUAL REPORT 2008

Letter to Shareholders SEMI-ANNUAL REPORT 2008 Letter to Shareholders SEMI-ANNUAL REPORT 2008 Dear Shareholder You have in your hand the first shareholder letter issued by Nobel Biocare. Thanks to the conversion of Nobel Biocare s bearer shares into

More information

ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update

ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update -Key First Quarter 2018 Clinical Milestones Achieved Patient randomization completed in Phase 2b EDELWEISS trial of OBE2109

More information

Forward-Looking Statements

Forward-Looking Statements Investor Presentation May 2012 Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.

More information

SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS

SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS SPHERIX Investor Relations Phone: (301) 897-2564 Email: info@spherix.com SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS BETHESDA, MD, May 21, 2010 - Spherix Incorporated (NASDAQ CM: SPEX), an innovator

More information

Growth in core businesses offsets weaker non-interest income. DBS Group Holdings 1Q 2005 Financial Results Presentation to Media and Analysts

Growth in core businesses offsets weaker non-interest income. DBS Group Holdings 1Q 2005 Financial Results Presentation to Media and Analysts Growth in core businesses offsets weaker non-interest income April 29, 2005 DBS Group Holdings 1Q 2005 Financial Results Presentation to Media and Analysts This presentation is available at www.dbs.com/investor

More information

Endesa 1Q 2017 Results 09/05/2017

Endesa 1Q 2017 Results 09/05/2017 Endesa 1Q 2017 Results 09/05/2017 1. Highlights and key financial figures 2. Endesa s performance in 1Q 2017 market context 3. Financial results 4. Final remarks 2 1. Highlights and key financial figures

More information

ObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update

ObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update ObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update - All Three Development Compounds Progressing with Key Clinical Milestones Over the Next 12 Months - Geneva, Switzerland

More information

Forward Looking Information

Forward Looking Information Vital Signs, Inc. Forward Looking Information Except for historical information discussed, the statements made today are forward-looking statements that involve risks and uncertainties. Investors are cautioned

More information

DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM

DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM November 28, 2017 DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM Dr. Jürgen Wunram Agenda Diebold Nixdorf AG History and shareholder structure Market trends, strategy and progress of integration Diebold Nixdorf

More information

ADM to Acquire Neovia and Probiotics International Limited. July 2, 2018

ADM to Acquire Neovia and Probiotics International Limited. July 2, 2018 ADM to Acquire Neovia and Probiotics International Limited July 2, 2018 Safe Harbor Statement 2 Some of our comments constitute forward-looking statements that reflect management s current views and estimates

More information

ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update

ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update IMPLANT 4 trial of nolasiban in IVF starting in Q4 2018, European MAA filing expected late 2019 24-week data from Phase

More information

After simple testing that only takes minutes people with elevated test results are then recommended to see their physicians for follow-up.

After simple testing that only takes minutes people with elevated test results are then recommended to see their physicians for follow-up. New Medical Device Company Addresses Two Very High Demand Markets with its Proprietary Products. Trader Tracks likes this company as they provide reasonably priced equipment and testing while medical costs

More information

Slide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A

Slide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 1 Financial update and closing remarks Jesper Brandgaard EVP and CFO RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 2 Forward-looking statements Novo Nordisk s reports filed with or

More information

Small-Cap Research. Diffusion Pharmaceuticals Inc. (DFFN-NASDAQ) DFFN: FDA Gives Final Guidance for Phase 3 Protocol for TSC in Inoperable GBM OUTLOOK

Small-Cap Research. Diffusion Pharmaceuticals Inc. (DFFN-NASDAQ) DFFN: FDA Gives Final Guidance for Phase 3 Protocol for TSC in Inoperable GBM OUTLOOK Small-Cap Research November 16, 2017 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Diffusion Pharmaceuticals Inc. (DFFN-NASDAQ) DFFN: FDA Gives Final

More information

Genomic Health. Kim Popovits, Chairman, CEO and President

Genomic Health. Kim Popovits, Chairman, CEO and President Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and

More information

Investor Presentation

Investor Presentation ASX:THC B u i l d i n g a M e d i c i n a l C a n n a b i s B u s i n e s s Investor Presentation November 2017 DISCLAIMER The material in this presentation (material) is not and does not constitute an

More information

Slide 1. Investor presentation. London 5 February 2019

Slide 1. Investor presentation. London 5 February 2019 Slide Investor presentation London 5 February 209 Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation

More information

Supplementary Data of Consolidated Financial Statements for the third quarter ended December 31, 2016

Supplementary Data of Consolidated Financial Statements for the third quarter ended December 31, 2016 Supplementary Data of Financial Statements for the third quarter ended December 31, 2016 January 31, 2017 NITTO DENKO CORPORATION CONTENTS Page Business 1 Segment Information 2 Segment Information By Geographic

More information

WELCOME TO ACTELION S AGM 2015

WELCOME TO ACTELION S AGM 2015 WELCOME TO ACTELION S AGM 2015 08 May 2015 Copyright 2015 Actelion Pharmaceuticals Ltd ACTELION S ANNUAL GENERAL MEETING 2015 MEETING STRUCTURE Opening Remarks Business Review 2014 Agenda & Proposals Jean-Pierre

More information

Investor Presentation. Q May 21, 2018

Investor Presentation. Q May 21, 2018 Investor Presentation Q3 2018 May 21, 2018 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking statements as contemplated by the Private Securities

More information

6.00% CAP Rate $5,600,000. DeerfieldPartners. John Giordani Art Griffith (415) Actual Store

6.00% CAP Rate $5,600,000. DeerfieldPartners. John Giordani Art Griffith (415) Actual Store Actual Store Low Price & Great Value $5,6, 6.% CAP Rate Open & paying rent--available for immediate sale Lower price point and great value Offered free & clear; loans available today with as little as

More information

Myriad Genetics Fiscal First-Quarter 2017 Earnings Call 11/01/2016

Myriad Genetics Fiscal First-Quarter 2017 Earnings Call 11/01/2016 Myriad Genetics Fiscal First-Quarter 2017 Earnings Call 11/01/2016 1 Forward Looking Statements Forward Looking Statements Some of the information presented here today may contain projections or other

More information

Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO

Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO Coloplast has four business areas all with global sales presence Group revenue

More information

Boston Scientific is advancing...

Boston Scientific is advancing... Boston Scientific is advancing... Our mission Our values Boston Scientific is dedicated to transforming lives through innovative Caring Meaningful Innovation High Performance medical solutions that improve

More information

Investor Presentation June 2012 NASDAQ: CEMI

Investor Presentation June 2012 NASDAQ: CEMI Investor Presentation June 2012 NASDAQ: CEMI Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act

More information

RAI: Strong key-brands performance delivers 2Q13 profit growth; Company reaffirms full-year EPS guidance

RAI: Strong key-brands performance delivers 2Q13 profit growth; Company reaffirms full-year EPS guidance Contact: Investor Relations: Morris Moore (336) 741-3116 Media: Jane Seccombe (336) 741-5068 Reynolds American Inc. P.O. Box 2990 Winston-Salem, NC 27102-2990 RAI 2013-10 RAI: Strong key-brands performance

More information

RULES OF CONDUCT OF INSIDERS RESPECTING

RULES OF CONDUCT OF INSIDERS RESPECTING T RULES OF CONDUCT OF INSIDERS RESPECTING RADING O F SECURITIES OF TFI International lnc. Amended and restated July 2015 Executive Summary As an insider of TFI International Inc. ( TFI International )

More information

CPH Chemie + Papier Holding AG. Investor Day. Perlen, 13 th September 2018

CPH Chemie + Papier Holding AG. Investor Day. Perlen, 13 th September 2018 CPH Chemie + Papier Holding AG Investor Day Perlen, 13 th September 2018 Agenda 2.00 pm Welcome 2.05 pm Presentation Course of Business 2018 2.50 pm Break 3.00 pm Presentation Perlen Packaging 3.30 pm

More information

Investor Presentation

Investor Presentation Investor Presentation Forward Looking Statements The information presented herein may contain projections, predictions, estimates and other forwardlooking statements within the meaning of Section 27A of

More information

FY2009 First Quarter Financial Results. SUZUKI MOTOR CORPORATION August 3, 2009

FY2009 First Quarter Financial Results. SUZUKI MOTOR CORPORATION August 3, 2009 FY2009 First Quarter Financial Results SUZUKI MOTOR CORPORATION August 3, 2009 Consolidated: Financial Summary Page 2 FY2009 1Q FY2008 4Q 09/4-6 09/1-3 Change FY2008 1Q 08/4-6 Change (Billion Yen) (A)

More information

Patrick J. Sullivan Chief Executive Officer. January 9, 2018 Investor Presentation

Patrick J. Sullivan Chief Executive Officer. January 9, 2018 Investor Presentation Patrick J. Sullivan Chief Executive Officer January 9, 2018 Investor Presentation Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's expectations, anticipations,

More information

RAI reports strong 2Q16 performance and positive outlook; Accelerates returns to shareholders

RAI reports strong 2Q16 performance and positive outlook; Accelerates returns to shareholders Contact: Investor Relations: Bob Bannon (336) 741-3359 Media: Jane Seccombe (336) 741-5068 Reynolds American Inc. P.O. Box 2990 Winston-Salem, NC 27102-2990 RAI 2016-22 RAI reports strong 2Q16 performance

More information

For personal use only

For personal use only FY2015 Half Year Results Presentation 6 months ended 30 September 2014 24 28 November 2014 1 First half result highlights H1 FY15 (6 months to 30 September 2014) PCP CC 1 Operating profit +8% +64% RAC

More information

Sumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical

Sumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical For immediate release November 25, 2004 Sumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical Sumitomo Chemical Co., Ltd. announced today that its subsidiary, Sumitomo

More information

Corporate Presentation October New growth cycle and value innovation

Corporate Presentation October New growth cycle and value innovation Corporate Presentation October 2017 New growth cycle and value innovation Index 1 Dental benefits: an incipient sector in Brazil 2 Inside OdontoPrev 3 Strategic competitive advantages 4 Financial and Operational

More information

Tandem Diabetes Care, Inc. (TNDM) - Medical Equipment - Deals and Alliances Profile

Tandem Diabetes Care, Inc. (TNDM) - Medical Equipment - Deals and Alliances Profile Tandem Diabetes Care, Inc. (TNDM) - Medical Equipment - Deals and Alliances Profile Tandem Diabetes Care, Inc. (TNDM) - Medical Equipment - Deals and Alliances Profile BioPortfolio has been marketing business

More information

Mount Prospect, Illinois

Mount Prospect, Illinois 1 Mile 3 Mile 5 Mile Population 1,189 1,659 337,66 Avg. HH Income $17, $85,16 $9,441 Landmark Walgreens Corporate HQ O Hare Airport Downtown Chicago Drive Time 1 minutes 15 minutes 35 minutes Walgreens

More information

Straumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America

Straumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America Media release Straumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America Group net revenue rises 2% (l.c.) as double-digit increases across America offset

More information

Jefferies Healthcare Conference June 6, 2018

Jefferies Healthcare Conference June 6, 2018 Jefferies Healthcare Conference June 6, 2018 Forward-Looking Statements Some of the statements included in this presentation, particularly those regarding the commercialization and ongoing clinical development

More information

Enel Américas 1Q 2018 results

Enel Américas 1Q 2018 results Enel Américas 1Q 2018 results 1Q 2018 results Highlights of the period EBITDA of 820 musd, an increase of 26% vs 1Q 2017 Generation EBITDA increased by 17% due to better prices in Argentina and consolidation

More information

ASX Announcement 22 June 2017

ASX Announcement 22 June 2017 ASX Announcement 22 June 2017 Investment Conference Presentation Attached is the presentation given by ITL Health Group at the Gold Coast Investment Showcase 21-22 June 2017 ITL Health Group ITL is an

More information

FORM8-K HILLENBRAND,INC.

FORM8-K HILLENBRAND,INC. UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION Washington,D.C.20549 FORM8-K CURRENTREPORT PursuanttoSection13or15(d)oftheSecuritiesExchangeActof1934 Date of Report (Date of earliest event reported): February1,2016

More information

Q2 INVESTOR KIT JANUARY-JUNE 2011

Q2 INVESTOR KIT JANUARY-JUNE 2011 Q2 INVESTOR KIT JANUARY-JUNE 2011 Swedish Match reporting segments Reporting segments following the transaction with STG on October 1, 2010 Snus and snuff - Swedish snus in Scandinavia and US - US moist

More information

MANAGEMENT. MGMT 0021 THE MANAGEMENT PROCESS 3 cr. MGMT 0022 FINANCIAL ACCOUNTING 3 cr. MGMT 0023 MANAGERIAL ACCOUNTING 3 cr.

MANAGEMENT. MGMT 0021 THE MANAGEMENT PROCESS 3 cr. MGMT 0022 FINANCIAL ACCOUNTING 3 cr. MGMT 0023 MANAGERIAL ACCOUNTING 3 cr. MANAGEMENT MGMT 0021 THE MANAGEMENT PROCESS 3 cr. An introduction designed to emphasize the basic principles, practices, and terminology essential to the understanding of contemporary business and its

More information

Zacks Small-Cap Research

Zacks Small-Cap Research Zacks Small-Cap Research Sponsored Impartial - Comprehensive August 29, 2018 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Opiant Pharmaceuticals,

More information

Myriad Genetics Fiscal First-Quarter 2019 Earnings Call 11/06/2018

Myriad Genetics Fiscal First-Quarter 2019 Earnings Call 11/06/2018 Myriad Genetics Fiscal First-Quarter 2019 Earnings Call 11/06/2018 Copyright 2017 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com. 1 Forward Looking Statements Forward Looking Statements

More information

Building a new model of sustainable chemistry. Meeting with Investors at VFB-Happening 2014 Karim Hajjar CFO

Building a new model of sustainable chemistry. Meeting with Investors at VFB-Happening 2014 Karim Hajjar CFO Building a new model of sustainable chemistry Meeting with Investors at VFB-Happening 2014 Karim Hajjar CFO Solvay at a glance Acceleration of Solvay s transformation Delivery in a challenging economic

More information

BANK HANDLOWY W WARSZAWIE S.A. 1Q 2009 consolidated financial results -1-

BANK HANDLOWY W WARSZAWIE S.A. 1Q 2009 consolidated financial results -1- BANK HANDLOWY W WARSZAWIE S.A. 1Q 29 consolidated financial results -1- Macroeconomic situation in 1Q 29 Deep drop in industrial output in January and February, albeit business confidence indicators suggest

More information

34 th Annual J.P. Morgan Healthcare Conference

34 th Annual J.P. Morgan Healthcare Conference JANUARY 2016 34 th Annual J.P. Morgan Healthcare Conference [ 1 ] Forward Looking Statements SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS In addition to historical information, this presentation contains

More information

MYnd Analytics, Inc. Update. Midtown Partners Research. Mental Health November 28, 2017

MYnd Analytics, Inc. Update. Midtown Partners Research. Mental Health November 28, 2017 Mental Health November 28, 2017 MYnd Analytics, Inc. OTC MYND We believe MYnd Analytics is commercializing a very valuable predictive technology in a field of medicine, mental disorders, where desicisions

More information

Clovis Oncology Announces Q Operating Results and Corporate Update. November 3, :05 PM ET

Clovis Oncology Announces Q Operating Results and Corporate Update. November 3, :05 PM ET Clovis Oncology Announces Q3 2016 Operating Results and Corporate Update November 3, 2016 4:05 PM ET Rucaparib New Drug Application (NDA) accepted for Priority Review in the treatment of advanced BRCA-mutant

More information

Delivering Results POSITIONED FOR GROWTH. Analyst & Investor Day October 14, 2015 Paul Guggenheim CEO, Patterson Dental

Delivering Results POSITIONED FOR GROWTH. Analyst & Investor Day October 14, 2015 Paul Guggenheim CEO, Patterson Dental Delivering Results POSITIONED FOR GROWTH Analyst & Investor Day October 14, 2015 Paul Guggenheim CEO, Patterson Dental PAUL GUGGENHEIM CEO, Patterson Dental Former owner and president, Guggenheim Brothers

More information

XXII: CTP Summarizes Scientific Case for Limiting Nicotine in Cigarettes. Company Update October 15, 2018 Industrial & Consumer Technology

XXII: CTP Summarizes Scientific Case for Limiting Nicotine in Cigarettes. Company Update October 15, 2018 Industrial & Consumer Technology Company Update Industrial & Consumer Technology (XXII - $2.81 - Buy) COMPANY NOTE JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com Sales and trading 7 a.m. to 7 p.m. ET,

More information

Fisher & Paykel Healthcare

Fisher & Paykel Healthcare Fisher & Paykel Healthcare Deutsche Bank / Craigs New Zealand Corporate Day 1 Sydney March 2014 Investment Highlights A leader in respiratory and OSA treatment devices Consistent growth strategy Estimated

More information

For personal use only

For personal use only Australian Securities Exchange Limited Companies Announcements Office SYDNEY 4 April, 2012 New Australian Drug Developer Lists on ASX Key points Growth-focused Australian drug and therapeutic development

More information

An exciting combination in a high growth, high margin Nutrition category. Name of chairman

An exciting combination in a high growth, high margin Nutrition category. Name of chairman An exciting combination in a high growth, high margin Nutrition category 2 Vevey, December 14, 2006 Disclaimer This presentation contains forward looking statements which reflect Management s current views

More information

Singapore Exchange Limited 1Q FY2009 Financial Results

Singapore Exchange Limited 1Q FY2009 Financial Results Singapore Exchange Limited 1Q FY2009 Financial Results 15 October 2008 Singapore Exchange 1 1Q FY2009 Financial Performance NPAT fell 35% from record 1Q FY2008 Operating profit flat compared to 4Q FY2008

More information

DARA Reports Year-End 2012 Financial Results

DARA Reports Year-End 2012 Financial Results April 1, 2013 DARA Reports Year-End 2012 Financial Results Company Provides a Commercial Portfolio and Development Pipeline Business Update RALEIGH, NC -- (MARKETWIRE) -- 04/01/13 -- DARA BioSciences,

More information

OBALON THERAPEUTICS, INC. (OBLN) The first and only FDA-approved swallowable, gas-filled intragastric balloon for weight loss

OBALON THERAPEUTICS, INC. (OBLN) The first and only FDA-approved swallowable, gas-filled intragastric balloon for weight loss OBALON THERAPEUTICS, INC. (OBLN) The first and only FDA-approved swallowable, gas-filled intragastric balloon for weight loss Forward looking statements Except for statements of historical fact, information

More information

Altria Group Inc (MO-NYSE)

Altria Group Inc (MO-NYSE) March 20, 2015 Altria Group Inc (MO-NYSE) Current Recommendation SUMMARY DATA NEUTRAL Prior Recommendation Underperform Date of Last Change 08/12/2009 Current Price (03/19/15) $51.27 Target Price $54.00

More information

RAI increases 3Q13 earnings on strong operating performance; tightens full-year EPS guidance

RAI increases 3Q13 earnings on strong operating performance; tightens full-year EPS guidance Contact: Investor Relations: Morris Moore (336) 741-3116 Media: Jane Seccombe (336) 741-5068 Reynolds American Inc. P.O. Box 2990 Winston-Salem, NC 27102-2990 RAI 2013-13 RAI increases 3Q13 earnings on

More information

Consolidated: Financial Summary

Consolidated: Financial Summary FY2010 First Quarter Financial Results SUZUKI MOTOR CORPORATION 3 August 2010 Consolidated: Financial Summary Page2 FY2010 1Q FY2009 1Q (2010/4-6) (2009/4-6) Change Net sales 656.3 577.1 +79.2 +13.7% Operating

More information

Universal Biosensors, Inc.

Universal Biosensors, Inc. Universal Biosensors, Inc. ARBN 121 559 993 Buchan Three Tickers Presentation 18 th September 2013 1 Important Disclaimer This presentation is intended to provide a general outline only and is not intended

More information

4Q and Full Year 2017 Financial Results Call February 7, 2018

4Q and Full Year 2017 Financial Results Call February 7, 2018 4Q and Full Year 2017 Financial Results Call February 7, 2018 Agenda Topic Welcome Opening Remarks 4Q 2017 Results Commercial Progress Question & Answer Speakers Amy Sullivan, SVP, Corporate Affairs Greg

More information

Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO

Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO Forward-looking statements The forward-looking statements contained in this presentation,

More information

Corporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015

Corporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015 (Nasdaq:EVAR) Corporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015 Safe Harbor This presentation contains forward-looking statements as that term is defined in the Private Securities Litigation

More information

Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014

Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014 Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) ( ) H1 2014 revenues and results - 24 July 2014 Forward-looking statement This presentation contains

More information

FY2016 1H Results. Cookpad Inc.

FY2016 1H Results. Cookpad Inc. FY2016 1H Results Cookpad Inc. 1 1H Highlights Premium Service -Premium Service revenue increased by 39.6% YoY. -Number of premium members grew by 12.0% YoY to exceed 1.85 million. Advertising -Advertising

More information

Special Meeting in Lieu of Annual Meeting of Shareholders

Special Meeting in Lieu of Annual Meeting of Shareholders Special Meeting in Lieu of Annual Meeting of Shareholders Thursday, June 19, 2008 James A. Bianco, M.D. President and CEO Agenda Call meeting to order Introduction of the inspector of elections, secretary,

More information

ABSOLUTE NNN LEASE 19 Years Remaining 8815 Stagecoach Rd. Little Rock, AR 72210

ABSOLUTE NNN LEASE 19 Years Remaining 8815 Stagecoach Rd. Little Rock, AR 72210 ABSOLUTE NNN LEASE 19 Years Remaining 8815 Stagecoach Rd. Little Rock, AR 72210 Price- $6,330,275 Cap Rate-5.45% Absolute Net Lease with 19 Years Remaining on Initial Lease Term. Lease Guaranteed by Walgreen

More information

biomérieux - First-Half 2009 Business Review

biomérieux - First-Half 2009 Business Review PRESS RELEASE biomérieux - First-Half 2009 Business Review First-Half 2009 Sales Up 6% at constant exchange rates and scope of consolidation Up 10.3% at constant exchange rates, including business development

More information

Results Briefing. 15 ~ 17 May 2007

Results Briefing. 15 ~ 17 May 2007 Results Briefing 1Q Q & 3 Months ended 31 Mar. 2007 15 ~ 17 May 2007 Content Key highlights Financial Corporate Financial results Industry overview Q&A Appendix 2 2 Key Highlights for the Period Key Highlights

More information

2014 Full Year Results Presentation. Year ended 31 March 2014

2014 Full Year Results Presentation. Year ended 31 March 2014 2014 Full Year Results Presentation Year ended 31 March 2014 26-30 May 2014 1 Full year result highlights 12 months to 31 March 2014 NZ$M PCP CC 1 Record net profit after tax 97.1 +26% +46% Record operating

More information

Visionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics

Visionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics Dear VPEG Limited Partner, We hope this investor update finds you well. We're pleased to share with you an important update below on the following: Visionary Private Equity Group is Pleased to Announce

More information